IMM 1.64% 30.0¢ immutep limited

Media, page-544

  1. 2,641 Posts.
    lightbulb Created with Sketch. 326
    Just some musings re head and neck ph2b top line results
    Topline results of Phase 2b trials are typically first disclosed through press releases so that key stakeholders (patients and their advocacy groups, physicians, clinical trials practitioners, investors, etc.) can have timely access to a high level summary of the important findings. The sponsors of the trials often will save more detailed findings for future medical conference presentations and/or peer-reviewed journal publications
 
watchlist Created with Sketch. Add IMM (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.